Apogee Therapeutics (APGE) reported a 2024 net loss Monday of $182.1 million, widening from a loss of $84 million a year earlier.
Analysts polled by FactSet expected a loss of $177.9 million.
At the end of the year, cash, cash equivalents and marketable securities were $731.1 million. The company said it expects its existing cash, cash equivalents and marketable securities to allow it to fund its operating expenses into Q1 2028.
Apogee shares were up 1.5% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.